DIAMOND BIOFUND INC (6901) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has a cash flow conversion efficiency ratio of -0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-21.12 Million ≈ $-665.27K USD) by net assets (NT$9.22 Billion ≈ $290.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DIAMOND BIOFUND INC (6901) liquidity interval to measure how many days the company can operate on defensive assets alone.
DIAMOND BIOFUND INC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how DIAMOND BIOFUND INC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DIAMOND BIOFUND INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIAMOND BIOFUND INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
Bahnhof AB Series B
ST:BAHN-B
|
0.072x |
|
Weltrend Semiconductor Inc
TW:2436
|
0.038x |
|
Il Dong Pharmaceutical Co Ltd
KO:249420
|
0.050x |
|
Uxin Ltd
NASDAQ:UXIN
|
-2.088x |
|
Nanning Department Store Co Ltd
SHG:600712
|
0.000x |
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
-0.013x |
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
0.011x |
Annual Cash Flow Conversion Efficiency for DIAMOND BIOFUND INC (2019–2025)
The table below shows the annual cash flow conversion efficiency of DIAMOND BIOFUND INC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see 6901 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$9.22 Billion ≈ $290.51 Million |
NT$-165.92 Million ≈ $-5.23 Million |
-0.018x | -116.39% |
| 2024-12-31 | NT$10.37 Billion ≈ $326.81 Million |
NT$1.14 Billion ≈ $35.89 Million |
0.110x | +821.33% |
| 2023-12-31 | NT$12.86 Billion ≈ $405.22 Million |
NT$-195.82 Million ≈ $-6.17 Million |
-0.015x | -135.56% |
| 2022-12-31 | NT$11.05 Billion ≈ $348.15 Million |
NT$473.09 Million ≈ $14.90 Million |
0.043x | +248.09% |
| 2021-12-31 | NT$10.39 Billion ≈ $327.41 Million |
NT$-300.42 Million ≈ $-9.46 Million |
-0.029x | -260.45% |
| 2020-12-31 | NT$9.10 Billion ≈ $286.71 Million |
NT$-72.99 Million ≈ $-2.30 Million |
-0.008x | +38.98% |
| 2019-12-31 | NT$3.01 Billion ≈ $94.85 Million |
NT$-39.57 Million ≈ $-1.25 Million |
-0.013x | -- |
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.